Last reviewed · How we verify
Meningitec®
Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.
Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C. Used for Prevention of meningococcal meningitis and septicemia caused by Neisseria meningitidis serogroup C.
At a glance
| Generic name | Meningitec® |
|---|---|
| Also known as | MenC vaccine, Meningococcal C conjugate vaccine (Wyeth). |
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroup C polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains polysaccharide capsular material from N. meningitidis serogroup C conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune responses. This conjugation allows the vaccine to induce both IgG antibodies and immunological memory, providing protection against meningococcal meningitis and septicemia caused by serogroup C strains.
Approved indications
- Prevention of meningococcal meningitis and septicemia caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Headache
Key clinical trials
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (PHASE2)
- Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (PHASE3)
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningitec® CI brief — competitive landscape report
- Meningitec® updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI